400-500% laut US-Analyse!!! - 500 Beiträge pro Seite

[Truthforever]

IMNR bekannt durch sein AIDS-Mittel ist mit einem Kursziel von 8-10$ zum Kauf empfohlen worden.

Nach den Gewinnmitnahmen von Gestern dürfte der Kurs jetzt wieder Richtung 5$ laufen...

[Truthforever]

Dawson James Securities Initiates Coverage On Immune Response Corp. (IMNR) With A Buy Rating And A 12-Month Price Target Of $8-$10

Thursday , September 04, 2003 14:11 ET

FORT LAUDERDALE, Fla., Sep 04, 2003 /PRNewswire via COMTEX/ -- Robert Wasserman, Director of Research for Dawson James Securities, a Division of ViewTrade Financial, has initiated coverage on Immune Response Corporation (Nasdaq: IMNR) with a buy rating and a 12-month price target of $8-$10.

Dawson James is a research-oriented healthcare/biotech boutique investment firm with offices in Florida and New Jersey. Dawson James focuses on delivering high quality independent research on firms in Florida and the Southeast to both retail and institutional investors.

IMNR, based in Carlsbad, CA, is a biopharmaceutical company developing a therapeutic vaccine for the treatment of human immunodeficiency virus (HIV) infection. Currently, IMNR is focusing its research and development efforts on REMUNE, an immune-based therapy for HIV infection which was been the subject of over 18 clinical studies and 2,000 patients over the past ten years.

Mr. Wasserman believes that Immune Response can gain additional share valuation in the near-term with the successful progress of REMUNE clinical trials in Europe and additional discussions with the US FDA. The $8-$10 price target for IMNR stock is based on the share price two years ago, before disappointing initial determinations were made by the Spanish data review board. Mr. Wasserman feels that new studies in Europe are progressing to overcome this initial reluctance and discussions are being held with the US FDA.

Robert Wasserman is responsible for research in the areas of specialty and generic pharmaceuticals, healthcare services and biotechnology. Mr. Wasserman has over fifteen years` experience in equity research specializing in all areas of health care. Among the areas covered are pharmaceuticals, medical devices, healthcare services and biotechnology. He has analyzed and written reports on over 100 publicly traded health care companies. This research report is available by contacting Mr. Wasserman at [phone], or by e- mail: [e-mail].

Information and statements contained herein, other than historical information, should be considered forward-looking, which involve risk and uncertainties. The securities referenced are speculative in nature and may not be suitable for your investment objective. Dawson James may have a long or short position in the securities; its officers, directors and affiliates may maintain positions in the securities referenced that may change at any time without notice.

For further information about Dawson James contact Robert D. Keyser Jr. at 954-928-0928 or email [e-mail] .

Dawson James Securities is a member of the National Association of Securities Dealers, CRD number 47116.

SOURCE Dawson James Securities


CONTACT: Robert D. Keyser Jr., Dawson James Securities, [phone]
or [e-mail]

URL: http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved

[hahnebchen]

Diese Aussagen der Firma kenne ich seit etlichen Jahren.

Hierauf basierend habe ich vor Jahren auch schon vergeblich versucht, Geld mit der Aktie zu verdienen.

Ich kenne keine Biofirma, die schon solange vergeblich versucht, ein Medikament marktreif zu machen.

Gruss

Hahnebüchen

[Truthforever]

Ask in FRA 2,05!

Fairer Kurs zum Schlusskurs in USA!

[Calytyper]

wieso sollte man eine Firma kaufen,die noch nicht mal eine Zulassung der FDA hat ??
Wieviel Umsatz bzw.Gewinn oder Verlust macht die Firma ??
Wieviel Geld hat die Firma noch um zu überleben ??
Hat jemand infos ??

Danke !!